MARKET WIREYahoo Finance UK • 11h ago
Caris Life Sciences, Inc. (CAI) stock price, news, quote and historyYahoo Finance UK report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
Why CAI Stock dropped -5.01% Today — RQD Quant Desk Flash
$34.33 -5.01% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $34.10
Caris Life Sciences Inc. (CAI) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (steady margins, 4% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $10.21B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CAI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Caris Life Sciences Inc. (NASDAQ: CAI) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $34.33 (-5.01% 1D, market cap $10.21B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, CAI ranks #58 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CAI compare to MOH and HSIC in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), CAI carries a Roarable B (73/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 4.4%. By comparison, MOH (Molina Healthcare Inc) holds a D+ grade (54/100 RQD, P/E 22.0x, ROIC 17.2%, cap $10.39B) and HSIC (Henry Schein Inc.) posts a C- grade (60/100 RQD, P/E 23.0x, ROIC 11.2%, cap $9.63B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CAI?
▼
Per CAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002019410), Caris Life Sciences Inc. generated $812.0M in revenue (+97.0% YoY), -$68.1M in net income, and $66.9M in free cash flow against $1.13B in total assets and $378.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $34.10 (-0.66%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 8.2% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
3-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw B · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+6.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CAI)Realized 20D OHLCV Swing Band: ±12.4%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY CAI SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (25% of score)
20D Institutional Volume Accumulation (±12.4% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)
Altman Z-Score 9.79 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)
Disciplined Float (-0.04% YoY Shares) & executive Form 4 sales trim 8 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$29.53+5.4% Next Q
65
Q2 (-2Q)Grade B-$31.11+8.2% Next Q
68
Q3 (-1Q)Grade B$33.67+2% Next Q
70
CurrentGrade B$34.33+7.1% Hist 90D α
73
Trajectory: C+ (65) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the CAI Bull Thesis Could Fail
Even with a 73/100 (B) score, CAI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($29.56) or 200D SMA ($21.67) invalidates the momentum regime and cuts Target Base ($36.65) toward Bear Floor ($28.15).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CAI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CAI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CAI Stock dropped -5.01% Today — RQD Quant Desk Flash
Caris Life Sciences Inc. (CAI) dropped -5.01% to $34.33, trading at 90% of its 52-week range ($14.19 – $36.5). High-quality cash engine (steady margins, 4% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 90% of its 52-week range ($14.19 – $36.5) with RSI-14 at 67.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.4% around $34.33 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 52% gross margin and $66.9M annual free cash flow.
Live CAI Headlines & Catalysts
MARKET WIRESimply Wall St • 14h ago
Caris Life Sciences (NasdaqGS:CAI) Stock Forecast & Analyst PredictionsSimply Wall St report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 17h ago
Caris Life Sciences, Inc. Stock 12‑Month Price Target Raised to $30.23, Implies 10% UpsideTradingView report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 20h ago
Caris Life Sciences (NASDAQ:CAI) Shares Up 7.6% - Still a Buy?MarketBeat report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 23h ago
Caris Life Sciences (CAI) Stock Price, News & AnalysisStock Titan report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
CATALYSTMarketBeat • 1d ago
Caris Life Sciences (NASDAQ:CAI) Stock Price Target Raised at JPMorgan Chase & Co.MarketBeat report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out forYahoo Finance report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Jordan Spieth stars in a campaign for an AI-powered blood test to help detect cancer earlyStock Titan report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 4d ago
Viatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CATALYSTBenzinga • 6d ago
BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $33 to $38.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (CAI Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CAI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +83.68%▲ ASCENDING CHANNEL
2026-11-02O $35.45H $36.14L $34.33C $34.33VOL 3.79M
RES: $37.05SUP: $16.49SMA50: $29.56SMA200: $21.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CAI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
14.6%/yr Implied 5Y Growth
vs. +97.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CAI today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CAI. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CAI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CAI)
Health Care Rank #58 of 1016
⚔️ MOH vs CAI Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CAI vs. MOH, HSIC, OSCR, GRAL)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Caris Life Sciences Inc. (CAI) ranks #58 by composite RQD confidence (73/100, grade B) and #112 by equity capitalization ($10.21B). Within this direct 5-issuer industry benchmark cohort, MOH leads on earnings valuation at 22.0x trailing P/E, while MOH leads on capital efficiency and profitability with 17.2% ROIC and 13.1% gross margin. CAI currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CAI
ACTIVE
Caris Life Sciences Inc. | B | 73/100 | — | — | 4.4% | -5.01% | $10.21B | Benchmark Subject |
| MOH Molina Healthcare Inc | D+ | 54/100 | 22.0x | 13.1% | 17.2% | +2.93% | $10.39B | /moh-vs-cai → |
| HSIC Henry Schein Inc. | C- | 60/100 | 23.0x | 31.1% | 11.2% | -1.80% | $9.63B | /hsic-vs-cai → |
| OSCR Oscar Health Inc. | D+ | 53/100 | — | — | -35.0% | -1.36% | $9.50B | /oscr-vs-cai → |
| GRAL GRAIL Inc. | D+ | 54/100 | — | — | -18.0% | -9.75% | $7.10B | /gral-vs-cai → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002019410In its most recent audited fiscal period (FY2025, filed 2025-12-31), Caris Life Sciences Inc. (CAI) reported GAAP revenue of $812.0M (+97.0% vs. FY2024 revenue of $412.3M , and +165.3% cumulative change since FY2023) , GAAP net income of -$68.1M, operating cash flow of $83.2M, and free cash flow of $66.9M (+126.4% YoY). On the balance sheet, CAI closed FY2025 with $1.13B in total assets against $378.8M in total debt (Altman Z-Score: 9.79, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $812.0M | -$68.1M | $83.2M | $66.9M | $1.13B | $378.8M |
| FY2024 (FY) | 2024-12-31 | $412.3M | -$281.9M | -$245.2M | -$253.6M | $343.7M | $319.4M |
| FY2023 (FY) | 2023-12-31 | $306.1M | -$341.4M | -$276.1M | -$289.9M | $5.62B | $1.31B |
3. CAI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CAI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Caris Life Sciences Inc. (NASDAQ: CAI) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $34.33 (-5.01% 1D, market cap $10.21B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 18/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, CAI ranks #58 in composite RQD confidence.
How does CAI compare to MOH and HSIC in the Health Care sector?
Within the Health Care sector (Medical Specialities), CAI carries a Roarable B (73/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of 4.4%. By comparison, MOH (Molina Healthcare Inc) holds a D+ grade (54/100 RQD, P/E 22.0x, ROIC 17.2%, cap $10.39B) and HSIC (Henry Schein Inc.) posts a C- grade (60/100 RQD, P/E 23.0x, ROIC 11.2%, cap $9.63B). Among the 5-stock peer group, MOH leads on earnings multiple (22.0x) while MOH leads on capital efficiency (17.2% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CAI?
Per CAI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002019410), Caris Life Sciences Inc. generated $812.0M in revenue (+97.0% YoY), -$68.1M in net income, and $66.9M in free cash flow against $1.13B in total assets and $378.8M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CAI trading relative to its 50-day, 200-day, and 52-week technical levels?
CAI last traded at $34.33 (-5.01% on volume of 3,672,988 shares), positioning the stock +16.14% above its 50-day simple moving average ($29.56) and +58.42% above its 200-day simple moving average ($21.67). Across its 52-week range of $14.19 to $36.50, CAI sits at the 90.3% percentile with a 14-day RSI of 67.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.4% ($30.07 to $38.59).
CAI Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CAI stock moving today?
Why CAI Stock dropped -5.01% Today — RQD Quant Desk Flash. High-quality cash engine (steady margins, 4% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 73/100 (B)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CAI — Caris Life Sciences Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:34Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CAI scores 73 out of 100, graded B and labeled "Roarable Buy — Good Risk/Reward." The five pillars are:
- Fundamental Cash Engine: 14 / 20. Per the Roarable RQD rating, this reflects ROIC of 4.4% and an FCF yield of 0.65%. For an investor, these are modest return-on-capital and cash-generation figures, meaning the business currently converts little of its capital and market value into free cash flow.
- Whale 13F Flow: 18 / 20. The strongest pillar, described as institutional accumulation and options positioning. This suggests sophisticated holders have been building positions, a supportive signal, though the underlying 13F detail is not itemized in the source data.
- Insider Conviction: 12 / 20. Based on SEC Form 4 and Congressional PTR cluster flow. This is a middling reading; insider activity is present but not a dominant bullish signal.
- Macro Regime Fit: 13 / 20. Per the Roarable RQD rating, beta is 0.91 with notable sector sensitivity. A beta below 1 implies somewhat lower volatility than the broad market, which may appeal to investors seeking moderated swings, but the sector sensitivity caveat limits the score.
- Forensic Balance Sheet: 16 / 20. Per the Roarable RQD rating, Altman Z is 9.79, Piotroski F is 8 of 9, and Debt/Equity is 0.66. These are the strongest fundamental supports in the profile and indicate a sound balance-sheet posture.
Taken together, the investment case rests on institutional accumulation and a strong balance sheet, offset by thin cash returns and valuation that the source data flags as stretched (EV/EBITDA of 95). Valuation tradeoffs are significant: the stock trades at a forward P/E of 21 but carries negative trailing EPS of -0.24, so near-term earnings support depends on forecasts rather than realized results.
Business
Caris Life Sciences Inc. is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry, per the company profile. The profile identifies the company's market capitalization as $10.2B. The source data does not describe the company's products, customers, or revenue model.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | $45.1M | $-68.1M | N/A | $66.9M | $796.3M | $378.8M |
| FY 2024 | $412.3M | $-257.1M | $-281.9M | N/A | $-253.6M | $64.0M | $319.4M |
| FY 2023 | $306.1M | $-319.6M | $-341.4M | N/A | $-289.9M | N/A | $1314.4M |
Per the SEC financials, revenue grew from $306.1M (FY 2023) to $812.0M (FY 2025), and operating income moved from a loss to $45.1M in FY 2025, though FY 2025 net income remained negative at $-68.1M. Per the market data, operating margin is 5.6% and net margin is -8.4%. ROIC is 4.4%. Per the Roarable RQD rating, the Altman Z-Score is 9.79, the Piotroski F-Score is 8 of 9, and Debt/Equity is 0.66, indicating a strong balance-sheet posture. Reported debt declined from $1314.4M in FY 2023 to $378.8M in FY 2025.
Recent Catalysts & News Wire Analysis
Six headlines reference CAI. Per the recent news feed, a TradingView item reports a 12-month price target raised to $30.23 implying 10% upside, tagged as a green catalyst. A MarketBeat item reports a price target raised at JPMorgan Chase & Co., also tagged green. Other items, including Simply Wall St, MarketBeat ("Shares Up 7.6%"), and Stock Titan, are tagged yellow as market-wire coverage. Risk watch items are not separately identified in the source data. The Butterfly Supply-Chain Graph lists no proprietary signals.
Open Questions
- What products and customers generate the FY 2025 revenue of $812.0M, and what drove the swing to positive operating income?
- Why is trailing P/E unavailable while forward P/E is 21, and what earnings path underlies that forecast?
- What specific institutional holders and options positions underlie the 18/20 whale-flow score?
- Which insider transactions drive the 12/20 insider conviction score, and over what timeframe?
- What explains the EV/EBITDA of 95 relative to the 4.4% ROIC and 0.65% FCF yield?
CAI Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Caris Life Sciences Inc. (CAI) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance UK • 11h ago
Caris Life Sciences, Inc. (CAI) stock price, news, quote and history Yahoo Finance UK report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 14h ago
Caris Life Sciences (NasdaqGS:CAI) Stock Forecast & Analyst Predictions Simply Wall St report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 17h ago
Caris Life Sciences, Inc. Stock 12‑Month Price Target Raised to $30.23, Implies 10% Upside TradingView report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 20h ago
Caris Life Sciences (NASDAQ:CAI) Shares Up 7.6% - Still a Buy? MarketBeat report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 23h ago
Caris Life Sciences (CAI) Stock Price, News & Analysis Stock Titan report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 1d ago
Caris Life Sciences (NASDAQ:CAI) Stock Price Target Raised at JPMorgan Chase & Co. MarketBeat report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for Yahoo Finance report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Jordan Spieth stars in a campaign for an AI-powered blood test to help detect cancer early Stock Titan report covering Caris Life Sciences Inc. (CAI) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CAI Bull vs. Bear Conversation Board — What's Your Call at $34.33?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CAI 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $42.65 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CAI (B • RQD 73/100) a Buy at $36.14?
Welcome to the CAI (Caris Life Sciences Inc.) Roar Pit. Current RQD Composite is 73/100 (Roarable Buy — Good Risk/Reward) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $30.36 (-16.0%)
Spot @ $36.14 Pump the brakes on CAI — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CAI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Caris Life Sciences Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $43.01 (+19.0%)
Spot @ $36.14 CAI cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CAI, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $36.14 (52-wk range $14.19 - $36.50), any beat on forward guidance forces shorts and underweight funds to chase.